Detalhe da pesquisa
1.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728430
2.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Blood
; 141(14): 1685-1690, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608320
3.
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.
Blood
; 142(19): 1633-1646, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390336
4.
Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.
Eur J Nucl Med Mol Imaging
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456971
5.
Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients.
Haematologica
; 108(12): 3308-3320, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381752
6.
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
BMC Cancer
; 23(1): 1132, 2023 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990162
7.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
8.
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
Haematologica
; 107(8): 1891-1901, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045690
9.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 379(19): 1811-1822, 2018 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403938
10.
Venetoclax in myeloma: to B, or not to B.
Blood
; 143(1): 4-5, 2024 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175678
11.
Novel immunotherapies in multiple myeloma - chances and challenges.
Haematologica
; 106(10): 2555-2565, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196164
12.
B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
Int J Cancer
; 147(8): 2029-2041, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32270481
13.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood
; 132(6): 587-597, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29884741
14.
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.
Acta Neuropathol
; 139(1): 175-192, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31473790
15.
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.
Br J Haematol
; 187(4): 447-458, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31388996
16.
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
Eur J Haematol
; 103(2): 107-115, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31112311
17.
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
Int J Mol Sci
; 20(5)2019 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30871078
18.
IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.
Cancer Immunol Immunother
; 67(11): 1695-1707, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30128739
19.
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Blood
; 128(9): 1226-33, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458004
20.
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
Hematol Oncol
; 36(1): 258-261, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28840598